Emcure Pharmaceuticals Q1 Results FY27 : Uniresearch Prediction, Analyst Views and Watchpoints

June 26, 2026
Posted by: Kunal Singla
Category: News

Emcure Pharmaceuticals Q1 Results FY27: Revenue Rs 2,432 Cr (+15.8% YoY) | PAT Rs 302 Cr (+40.5% YoY), Uniresearch estimate.

Emcure Pharmaceuticals Q1 Results FY27: Uniresearch projects Q1 FY27 Revenue at Rs 2,432 Cr (+15.8% YoY) and PAT at Rs 302 Cr (+40.5% YoY), based on the Uniresearch estimate. Q4 FY26 consolidated Revenue stood at Rs 2,470 Cr and PAT at Rs 244 Cr per consolidated quarterly financial data. Prepared by Kunal Singla, Associate Director.

Click Here – Get Free Investment Predictions

Table of Contents

Emcure Pharmaceuticals Q1 Results FY27: Uniresearch Prediction

Metric	Q1 FY26 Actual	Q1 FY27 Uniresearch Prediction	YoY Change
Revenue (Rs Cr)	2,101	2,432	+15.8%
PAT (Rs Cr)	215	302	+40.5%

Source: Q1 FY26 actuals from consolidated quarterly financial data. Emcure Pharmaceuticals Q1 Results FY27 prediction applies Uniresearch trailing growth rates (Revenue +15.8%, PAT +40.5%) to Q1 FY26 verified actuals. Not guaranteed outcomes.

Track Emcure Pharmaceuticals Live on Univest

Q4 FY26 Performance: Base for the Prediction

The Emcure Pharmaceuticals Q1 Results FY27 prediction is anchored on Q4 FY26 consolidated Revenue of Rs 2,470 Cr and PAT of Rs 244 Cr per consolidated quarterly financial data. These Q4 FY26 actuals, combined with Uniresearch trailing growth estimates, form the basis of the Q1 Results FY27 Uniresearch projection.

The sequential comparison also provides useful context for interpreting the Q1 Results FY27 numbers. Q4 FY26 Revenue of Rs 2,470 Cr reflects year-end procurement and execution cycles that may not repeat equally in the Q1 FY27. For this reason, the more meaningful benchmark for investors is the year-on-year comparison: Q1 FY27 against Q1 FY26 actual Revenue of Rs 2,101 Cr, where the Uniresearch estimate targets +15.8% growth. Both the YoY and sequential reads should be monitored when the actual Q1 Results FY27 numbers are declared.

Uniresearch Estimate Behind the Emcure Pharmaceuticals Q1 Results FY27 Projection

The Emcure Pharmaceuticals Q1 Results FY27 prediction is derived from Uniresearch trailing analysis, which estimates FY27 Revenue growth of +15.8% and PAT growth of +40.5% year-on-year. Uniresearch applies these consensus growth rates to Q1 FY26 actuals to arrive at the Q1 FY27 projection of Rs 2,432 Cr Revenue and Rs 302 Cr PAT.

The Q1 FY27 estimation methodology for Emcure Pharmaceuticals is worth clarifying for investors. Uniresearch applies full-year FY27 Uniresearch estimate growth rates (+15.8% Revenue, +40.5% PAT) to Q1 FY26 verified actuals to derive the Q1 FY27 projection of Rs 2,432 Cr Revenue and PAT Rs 302 Cr. This approach assumes the quarterly trajectory broadly mirrors the full-year consensus direction. Intra-year seasonality and one-time events can cause actual quarterly performance to diverge from this projection. Treat this Q1 FY27 Uniresearch estimate for Emcure Pharmaceuticals as a directional benchmark, not a point forecast.

Get Expert Stock Picks on Univest

Key Watchpoints for the Emcure Pharmaceuticals Q1 Results FY27

Revenue vs Consensus Target

Whether Q1 Results FY27 Revenue delivers in line with the Rs 2,432 Cr Uniresearch estimate (+15.8% YoY). Q4 FY26 Revenue was Rs 2,470 Cr.

PAT Margin Sustainability

PAT of Rs 302 Cr (+40.5% YoY) is the Q1 Results FY27 Uniresearch estimate. Q4 FY26 PAT was Rs 244 Cr. Margin stability signals operating leverage.

Management Commentary and Full-Year FY27 Guidance

Beyond the Q1 FY27 headline numbers, Emcure Pharmaceuticals’s management commentary at the results announcement will be watched for full-year FY27 guidance on revenue trajectory, margin direction, and capital allocation. A confident outlook from management following an in-line or beat result could support re-rating, while cautious guidance despite solid numbers may limit near-term upside. Track post-result commentary on the Univest Screener for a complete picture.

Risks to the Emcure Pharmaceuticals Q1 Results FY27 Prediction

Below-Consensus Revenue Growth

If actual Q1 Results FY27 Revenue underperforms the +15.8% growth target, the Rs 2,432 Cr prediction would be revised downward.

PAT Pressure from Costs or Provisions

One-time charges or higher costs could push PAT below Rs 302 Cr.

External and Macro Environment

The Emcure Pharmaceuticals Q1 Results FY27 performance is also exposed to macro-level risks beyond Emcure Pharmaceuticals’s direct control. Global commodity price movements, rupee-dollar exchange rate swings, domestic interest rate changes, and shifts in FII and DII sentiment toward the sector can affect input costs, realisations, and investor appetite simultaneously. A deteriorating macro environment in the Q1 FY27 could create downside risk to the Uniresearch Q1 FY27 projection even if company-specific execution remains on track.

Emcure Pharmaceuticals Q1 Results FY27: Conclusion

The Emcure Pharmaceuticals Q1 FY27 Uniresearch projection of Revenue Rs 2,432 Cr and PAT Rs 302 Cr is derived from Uniresearch trailing analysis. Track Emcure Pharmaceuticals live on the Univest Screener for real-time updates.

Use the Univest Screener to Track Emcure Pharmaceuticals Live

Download the Univest iOS App or Univest Android App for live Emcure Pharmaceuticals Q1 FY27 result alerts.

Disclaimer: Revenue and PAT actuals are sourced from consolidated quarterly financial data. Q1 Results FY27 projections are derived from Uniresearch estimate growth rates applied to Q1 FY26 actuals. These are consensus-based estimates, not guaranteed outcomes. Investments in securities are subject to market risk. For educational purposes only. SEBI RA INH000013776.

Frequently Asked Questions on Emcure Pharmaceuticals Q1 Results FY27

What is the Uniresearch prediction for Emcure Pharmaceuticals Q1 Results FY27?

Ans. Uniresearch projects Emcure Pharmaceuticals Q1 Results FY27 Revenue at Rs 2,432 Cr (+15.8% YoY) and PAT at Rs 302 Cr (+40.5% YoY), based on the Uniresearch estimate. Q1 FY26 actuals were Revenue Rs 2,101 Cr and PAT Rs 215 Cr.

What Uniresearch estimate is used for the Emcure Pharmaceuticals Q1 Results FY27 prediction?

Ans. The Emcure Pharmaceuticals Q1 Results FY27 prediction uses Uniresearch trailing analysis, projecting FY27 Revenue growth of +15.8% and PAT growth of +40.5% YoY. Average 12-month price target: Rs 2,766.

What were Q4 FY26 actuals behind the Emcure Pharmaceuticals Q1 Results FY27 projection?

Ans. Q4 FY26 consolidated Revenue was Rs 2,470 Cr and PAT was Rs 244 Cr per consolidated quarterly financial data.

How reliable is the Emcure Pharmaceuticals Q1 Results FY27 Uniresearch prediction?

Ans. The estimate is consensus-based, not a guaranteed outcome. Actual results may differ due to macro conditions and sector dynamics.

What base data is used for the Emcure Pharmaceuticals Q1 Results FY27 Uniresearch projection?

Ans. The Uniresearch projection for Q1 Results FY27 uses Q1 FY26 consolidated actuals (Revenue Rs 2,101 Cr, PAT Rs 215 Cr) as the base, sourced from Screener.in quarterly financial data. Trailing YoY growth rates (Revenue +15.8%, PAT +40.5%) are applied to these actuals to derive the Q1 Results FY27 estimate. Actuals and projections can be tracked on the Univest Screener.

What are the key risks to the Emcure Pharmaceuticals Q1 Results FY27 estimate?

Ans. Key risks: below-consensus revenue growth, margin compression, one-time provisions reducing PAT below Rs 302 Cr.

When will Emcure Pharmaceuticals declare the actual Emcure Pharmaceuticals Q1 Results FY27 data?

Ans. Emcure Pharmaceuticals will declare Q1 FY27 results after the quarter ends. Track live updates on the Univest Screener.

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.